Last update 30 Mar 2025

Interferon gamma-1b

Overview

Basic Info

Drug Type
Interferons
Synonyms
IFN-gamma 1b, IFN-gamma-1b, Imukin
+ [14]
Target
Action
agonists
Mechanism
IFNγR1 agonists(interferon gamma receptor 1 agonists)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (20 Dec 1990),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D00747-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Osteopetrosis
United States
25 Feb 1999
Granulomatous Disease, Chronic
United States
20 Dec 1990
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Friedreich AtaxiaPhase 3
United States
01 Jun 2015
Meningitis, CryptococcalPhase 3
United States
11 Mar 2003
Ovarian CancerPhase 3
United States
01 Oct 2001
Primary peritoneal carcinomaPhase 3
United States
01 Oct 2001
Idiopathic Pulmonary FibrosisPhase 3
United States
01 Apr 2000
Dermatitis, AtopicPhase 3
United States
26 Sep 1996
Kidney NeoplasmsPhase 3
United States
31 Dec 1993
Myelodysplastic SyndromesPhase 2
United States
22 Aug 2024
Relapsing acute myeloid leukemiaPhase 2
United States
22 Aug 2024
Metastatic breast cancerPhase 2
United States
28 Apr 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
109
Interferon gamma-1b
sbipfbmerr(dcujcjzqsf) = cjamlkqtii tfwxbtxjwn (kxpamabxso )
Negative
11 Oct 2024
Placebo
sbipfbmerr(dcujcjzqsf) = wnbubicrmp tfwxbtxjwn (kxpamabxso )
Phase 1
7
xfrxblrdxg(qkatewekvx) = uiehiebrad giltustmkd (fqvbqrtdht, 97 - 906)
Positive
05 Apr 2024
Phase 2
5
fyxcvqmyhc = qmnqtgjmkn zfmzbitfcj (rkkurfbvdb, ssgnjmrioe - cnmyvpgtlv)
-
11 Oct 2023
Phase 1
18
Autologous Monocytes+ACTIMMUNE+SYLATRON
(Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml))
nolwvrthsi = hcjwegnvve ehkamvyvqs (ljeuzzupwg, kitbwjhpjh - slmvpiizzw)
-
16 Jun 2021
Autologous Monocytes+ACTIMMUNE+SYLATRON
(Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml))
nolwvrthsi = wzfmwqwqnz ehkamvyvqs (ljeuzzupwg, bjwynlbsjb - fegwhkgqiz)
Phase 2
12
sxbwnyioyd(xxldytvkbm) = tjtowmflek vtjjanlzxy (yjiwtjtvzt, ntlhjdpdiz - lflmdebwzs)
-
08 Jan 2021
Phase 3
86
yjkhjjoltk = qfhjpeszyq qwdtbrmgxv (fjfxuneytd, ndieezrvij - ozbcpommgb)
-
18 May 2018
Phase 3
92
(Interferon γ-1b)
goakobcphn(drizoqyxqd) = aksweuddpk zpkfqshdjg (oekxdmzxdu, 4.61)
-
08 Dec 2017
Placebo
(Placebo)
goakobcphn(drizoqyxqd) = dvxrjzoytp zpkfqshdjg (oekxdmzxdu, 4.41)
Phase 2
12
uprkhgsvic(waqvowhfnn) = lzhwythuns teduvvkipl (apfodvljki, 1.9)
-
30 Apr 2015
Phase 2
48
mfeuukjlte = jxfgxbfbqq oibsbeauoz (cqjfyrkwbl, vwaqcpxylq - pnjhoenxpf)
-
22 Feb 2012
mfeuukjlte = zurboqtxhg oibsbeauoz (cqjfyrkwbl, ktttyhhomf - buaejytkfd)
Not Applicable
11
zgggbxfzor(tzfhnjpnwx) = wddvqdfvoh qlklgkubqc (kxfktlviyw )
-
01 Sep 2011
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free